Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2019 10:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Presents First Data on APL-2 in C3 Glomerulopathy at ASN Kidney Week

CRESTWOOD, Ky., and WALTHAM Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
November 07, 2019 17:30 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM Mass. and CRESTWOOD, Ky., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
November 05, 2019 07:30 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Reports Third Quarter 2019 Business Update and Financial Results

Dosed First Patient in Phase 3 Study of APL-2 for Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed $220 Million Offering of Convertible Senior Notes Due 2026 Cash...
October 11, 2019 16:01 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis to Present Data on APL-2 in Complement 3 Glomerulopathy at ASN Kidney Week 2019

Company also provides an update on plans in nephrology CRESTWOOD, Ky. and WALTHAM Mass., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq: APLS), a clinical-stage...
October 04, 2019 17:30 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRESTWOOD, Ky. and WALTHAM Mass., Oct. 04, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
September 27, 2019 17:30 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CRESTWOOD, Ky., and WALTHAM Mass., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
September 26, 2019 08:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
September 18, 2019 08:00 ET | Source: Apellis Pharmaceuticals, Inc.

Phase 2 Study Published in Ophthalmology Highlights Efficacy and Safety Data of Intravitreal APL-2 for Geographic Atrophy Secondary to Age-Related Macular Degeneration

CRESTWOOD, Ky., and WALTHAM Mass., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (NASDAQ:APLS) a clinical-stage biopharmaceutical company focused on the development of novel...
September 16, 2019 17:00 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Closing of Offering of Convertible Senior Notes

CRESTWOOD, Ky. and WALTHAM, Mass., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
September 12, 2019 08:22 ET | Source: Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes

CRESTWOOD, Ky., and WALTHAM, Mass., Sept. 12, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...